Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS

Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS

NAARDEN, The Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)--Mar 30, 2026-

Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial

Prilenia Therapeutics and Ferrer have enrolled the first participant in the Phase III PREVAiLS trial assessing pridopidine in early ALS.The post Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial appeared first on Hospital Management.